For research use only. Not for therapeutic Use.
Tavolixizumab（Cat No.:I042203）is a monoclonal antibody that targets the PD-1 (programmed cell death protein 1) receptor on T-cells. PD-1 plays a critical role in suppressing immune responses, allowing tumors to evade immune detection. By inhibiting PD-1, tavolixizumab aims to enhance the body’s immune system, promoting the recognition and destruction of cancer cells. It has been explored in clinical trials for various cancers, including solid tumors and hematologic malignancies, to assess its effectiveness in improving immune responses and patient outcomes when used alone or in combination with other therapies.
| CAS Number | 1635395-25-3 |
| Purity | ≥95% |
